Literature DB >> 19435886

PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.

Babette Schade1, Trisha Rao, Nathalie Dourdin, Robert Lesurf, Michael Hallett, Robert D Cardiff, William J Muller.   

Abstract

Overexpression and/or amplification of the ErbB-2 oncogene as well as inactivation of the PTEN tumor suppressor are two important genetic events in human breast carcinogenesis. To address the biological impact of conditional inactivation of PTEN on ErbB-2-induced mammary tumorigenesis, we generated a novel transgenic mouse model that utilizes the murine mammary tumor virus (MMTV) promoter to directly couple expression of activated ErbB-2 and Cre recombinase to the same mammary epithelial cell (MMTV-NIC). Disruption of PTEN in the mammary epithelium of the MMTV-NIC model system dramatically accelerated the formation of multifocal and highly metastatic mammary tumors, which exhibited homogenous pathology. PTEN-deficient/NIC-induced tumorigenesis was associated with an increase in angiogenesis. Moreover, inactivation of PTEN in the MMTV-NIC mouse model resulted in hyperactivation of the phosphatidylinositol 3'-kinase/Akt signaling pathway. However, like the parental strain, tumors obtained from PTEN-deficient/NIC mice displayed histopathological and molecular features of the luminal subtype of primary human breast cancer. Taken together, our findings provide important implications in understanding the molecular determinants of mammary tumorigenesis driven by PTEN deficiency and ErbB-2 activation and could provide a valuable tool for testing the efficacy of therapeutic strategies that target these critical signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435886      PMCID: PMC2707232          DOI: 10.1074/jbc.M109.018937

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

Authors:  Matt van de Rijn; Charles M Perou; Rob Tibshirani; Phillippe Haas; Olli Kallioniemi; Juha Kononen; Joachim Torhorst; Guido Sauter; Markus Zuber; Ossi R Köchli; Frank Mross; Holger Dieterich; Rob Seitz; Doug Ross; David Botstein; Pat Brown
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Transgenic Polyoma middle-T mice model premalignant mammary disease.

Authors:  J E Maglione; D Moghanaki; L J Young; C K Manner; L G Ellies; S O Joseph; B Nicholson; R D Cardiff; C L MacLeod
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.

Authors:  D Dankort; B Maslikowski; N Warner; N Kanno; H Kim; Z Wang; M F Moran; R G Oshima; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

5.  Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.

Authors:  J M Garcia; J M Silva; G Dominguez; R Gonzalez; A Navarro; L Carretero; M Provencio; P España; F Bonilla
Journal:  Breast Cancer Res Treat       Date:  1999-10       Impact factor: 4.872

Review 6.  PTEN, a unique tumor suppressor gene.

Authors:  P L Dahia
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

7.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.

Authors:  V Stambolic; M S Tsao; D Macpherson; A Suzuki; W B Chapman; T W Mak
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

8.  Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors.

Authors:  Keiko Miyoshi; Andrea Rosner; Masahiro Nozawa; Christopher Byrd; Fanta Morgan; Esther Landesman-Bollag; Xin Xu; David C Seldin; Emmett V Schmidt; Makato M Taketo; Gertraud W Robinson; Robert D Cardiff; Lothar Hennighausen
Journal:  Oncogene       Date:  2002-08-15       Impact factor: 9.867

9.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

Authors:  E R Andrechek; W R Hardy; P M Siegel; M A Rudnicki; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland.

Authors:  Gang Li; Gertraud W Robinson; Ralf Lesche; Hilda Martinez-Diaz; Zhaorong Jiang; Nora Rozengurt; Kay-Uwe Wagner; De-Chang Wu; Timothy F Lane; Xin Liu; Lothar Hennighausen; Hong Wu
Journal:  Development       Date:  2002-09       Impact factor: 6.868

View more
  36 in total

1.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

3.  Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.

Authors:  Saya H Ebbesen; Maurizio Scaltriti; Carl U Bialucha; Natasha Morse; Edward R Kastenhuber; Hannah Y Wen; Lukas E Dow; José Baselga; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

4.  Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.

Authors:  Juan Li; Dominique Davidson; Cleiton Martins Souza; Ming-Chao Zhong; Ning Wu; Morag Park; William J Muller; André Veillette
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

Review 5.  Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Toxicol Pathol       Date:  2010-01-15       Impact factor: 1.902

6.  Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.

Authors:  Jianqiang Bao; Alessandra Di Lorenzo; Kevin Lin; Yue Lu; Yi Zhong; Manu M Sebastian; William J Muller; Yanzhong Yang; Mark T Bedford
Journal:  Cancer Res       Date:  2018-10-23       Impact factor: 12.701

Review 7.  Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.

Authors:  Julie A Wickenden; Christine J Watson
Journal:  Breast Cancer Res       Date:  2010-04-09       Impact factor: 6.466

8.  Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Authors:  Carmen Blanco-Aparicio; Marta Cañamero; Yolanda Cecilia; Belén Pequeño; Oliver Renner; Irene Ferrer; Amancio Carnero
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

Review 9.  Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies.

Authors:  Eran R Andrechek; Joseph R Nevins
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

Review 10.  Genetically engineered mouse models of PI3K signaling in breast cancer.

Authors:  Sjoerd Klarenbeek; Martine H van Miltenburg; Jos Jonkers
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.